Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Current Assets (2021 - 2025)

Roivant Sciences' Current Assets history spans 5 years, with the latest figure at $4.7 billion for Q4 2025.

  • For Q4 2025, Current Assets rose 609.48% year-over-year to $4.7 billion; the TTM value through Dec 2025 reached $4.7 billion, up 609.48%, while the annual FY2025 figure was $5.0 billion, 25.73% down from the prior year.
  • Current Assets reached $4.7 billion in Q4 2025 per ROIV's latest filing, up from $4.5 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $6.7 billion in Q1 2024 to a low of $635.7 million in Q4 2023.
  • Average Current Assets over 5 years is $3.0 billion, with a median of $2.2 billion recorded in 2021.
  • Peak YoY movement for Current Assets: tumbled 61.39% in 2023, then skyrocketed 609.48% in 2025.
  • A 5-year view of Current Assets shows it stood at $2.3 billion in 2021, then fell by 28.03% to $1.6 billion in 2022, then crashed by 61.39% to $635.7 million in 2023, then grew by 3.33% to $656.8 million in 2024, then surged by 609.48% to $4.7 billion in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Current Assets are $4.7 billion (Q4 2025), $4.5 billion (Q3 2025), and $4.6 billion (Q2 2025).